基因工程腺病毒(H101)瘤内注射联合化疗治疗鼻咽癌的疗效观察

目的:观察瘤内注射基因工程腺病毒(H101)联合化疗治疗鼻咽癌的近期疗效和不良反应方法:符合入选标准的鼻咽癌患者54例,给予H101瘤内注射,每天一次,每次一支(5×1011病毒颗粒/0.5ml),连续5天,同时联合PF方案(DDP 20mg/m2静滴,d1～5,5-FU 500mg/m2静滴,d1～5)或AF方案(ADM 50mg/m2静注d1;5-FU 500mg/m2静滴,d1～5)化疗,21天为一周期,所有患者均接受2个周期的治疗.结果:在可评价的54例患者中注射病灶的总有效率为77.7%,其中CR 10例,PR 32例.主要不良反应为注射部位局部疼痛20.4%,非感染性发热40.7%,流感样症状9.3%,未见严重不良事件.结论:在全身化疗的同时瘤内注射基因工程腺病毒(H101)对鼻咽癌有明确的治疗作用,不良反应低,易为患者接受.

Clinical Observation of Intratumoral Injection of E1B Gene-deleted Adenovirus (H101) Combined with Chemotherapy in Treatment of Nasopharyngeal Carcinoma

Objective: To evaluate the efficacy and toxicity of intratumoral H101, a E1B-deleted adenovirus, in combination with chemotherapy on patients with nasopharyngeal carcinoma. Methods: A total of 54 patients with nasopharyngeal carcinoma were treated with H101, 5*1011 viral particle per day for 5 consecutive days. PF regimen (cisplatin 20mg/m2 ivgtt, qd*5d; 5-fluorouracil 500mg/m2 ivgtt, qd *5d) or AF regimen (adriamycin 50mg/m2 iv, d1; 5-fluorouracil 500mg/m2 ivgtt, qd *5d) was administered to patients at the same time. Treatment repeated every 3 weeks, and all patients received 2 cycles of chemotherapy. Results: Among 54 evaluable cases, the overall response rate was 77.7%, including 10 cases of CR and 32 cases of PR. Main side effects were injection site pain (20.4%) and fever (40.7%), and influenza-like symptoms (9.3%). Serious adverse events were not found in the course of treatment. Conclusion: The study shows that the combination of genetically E1B-deleted adenovirus (H101) possessed a distinct efficacy in patients with naso- pharyngeal carcinoma, and the toxicities were lower and well tolerated.